Erythropoietin for Neonatal Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erythropoietin Treatment in Neonatal Hypoxic-Ischemic Encephalopathy: Results from a Randomized Clinical Study

  • By

  • Helen G. Liley

  • Rod W. Hunt

  • Rachel L. O’Connell

  • Malcolm R. Battin

  • Iona Novak

  • Yvonne W. Wu

  • Roberta Ballard

  • Lisa Askie

  • Nadia Badawi

  • Alpana Ghadge

  • Susan E. Jacobs

  • Sandra E. Juul

  • Lucille Sebastian

  • Deepika Wagh

  • R. John Simes

  • PAEAN Study Investigators

  • Shannon Clough

  • Jennifer Bowen

  • Paul Colditz

  • Girsih Deshpande

  • Lisa Gold

  • Wendy Hague

  • Kei Lui

  • Dominic Wilkinson

  • Nicola Austin

  • Sarah Bellhouse

  • Max Berry

  • Clare Collins

  • Amanda Dyson

  • Antonio G de Paoli

  • Koert de Waal

  • Bevan Headley

  • Leah Hickey

  • James Holberton

  • David Hou

  • Alison L Kent

  • Vinayak Kodur

  • Richard Mausling

  • Scott Morris

  • Arun Nair

  • David Osborn

  • Victor Samuel Rajadurai

  • Nadia Schmidt

  • Jason Tan

  • Mark B Tracy

  • Flora Y Wong

  • Sarah Finlayson

  • Shannon Hunt

  • Carbo Yeung

  • Laurence Ralston

  • October 1, 2026

Share

  • 1

    Neonatal hypoxic-ischemic encephalopathy (HIE) results from inadequate oxygenation or blood flow to the fetal brain before delivery.

  • 2

    The PAEAN trial evaluated high-dose erythropoietin (EPO) for improving outcomes in infants with HIE receiving therapeutic hypothermia.

  • 3

    Eligibility for the trial included infants born at 35 weeks or later with indicators of birth depression and moderate or severe encephalopathy.

  • 4

    Infants received intravenous EPO or placebo in a 1:1 ratio, with treatment beginning within 24 hours after birth.

  • 5

    The primary outcome at 2 years was all-cause death or survival with moderate or severe developmental deficits.

Original Source(s)

Erythropoietin for Neonatal Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial

  • by Helen G. Liley, Rod W. Hunt, Rachel L. O’Connell, Malcolm R. Battin, Iona Novak, Yvonne W. Wu, Roberta Ballard, Lisa Askie, Nadia Badawi, Alpana Ghadge, Susan E. Jacobs, Sandra E. Juul, Lucille Sebastian, Deepika Wagh, R. John Simes, PAEAN Study Investigators, Shannon Clough, Jennifer Bowen, Paul Colditz, Girsih Deshpande, Lisa Gold, Wendy Hague, Kei Lui, Dominic Wilkinson, Nicola Austin, Sarah Bellhouse, Max Berry, Clare Collins, Amanda Dyson, Antonio G de Paoli, Koert de Waal, Bevan Headley, Leah Hickey, James Holberton, David Hou, Alison L Kent, Vinayak Kodur, Richard Mausling, Scott Morris, Arun Nair, David Osborn, Victor Samuel Rajadurai, Nadia Schmidt, Jason Tan, Mark B Tracy, Flora Y Wong, Sarah Finlayson, Shannon Hunt, Carbo Yeung, Laurence Ralston

  • October 1, 2026

Related Content

Children growing up amid polycrises: implications for child development and children with disabilities

Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

Cardiometabolic Disease Education and Health Services Among Public High Schools